Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis (Q28480930)

meta-analysis

1 reference

title

Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis (English)

0 references

1 reference

17 September 2019

1 reference

8 February 2021

1 reference

electrocardiography

1 reference

vandetanib

1 reference

inferred from abstract

1 reference

Jiajie Zang

1

Jiajie

Zang

1 reference

20 October 2023

Shunquan Wu

2

Shunquan

Wu

1 reference

20 October 2023

Lei Tang

3

Lei

Tang

1 reference

20 October 2023

Xudong Xu

4

Xudong

Xu

1 reference

20 October 2023

Jie Bai

5

Jie

Bai

1 reference

20 October 2023

Caicui Ding

6

Caicui

Ding

1 reference

20 October 2023

Yue Chang

7

Yue

Chang

1 reference

20 October 2023

Long Yue

8

Long

Yue

1 reference

20 October 2023

Enming Kang

9

Enming

Kang

1 reference

20 October 2023

Jia He

10

Jia

He

1 reference

Creative Commons Attribution 4.0 International

20 October 2023

language of work or name

English

0 references

publication date

17 February 2012

3 references

3 April 2019

17 September 2019

8 February 2021

3 references

3 April 2019

17 September 2019

8 February 2021

7

0 references

issue

2

0 references

page(s)

e30353

0 references

copyright license

3 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

17 September 2019

Europe PubMed Central

on focus list of Wikimedia project

8 February 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Bias in meta-analysis detected by a simple, graphical test

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Operating characteristics of a rank correlation test for publication bias

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Molecularly targeted oncology therapeutics and prolongation of the QT interval

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Effects of thyroid hormone on the cardiovascular system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Risk stratification in the long-QT syndrome.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Long QT syndrome caused by noncardiac drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

29 September 2017

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Subclinical hypothyroidism is characterized by increased QT interval dispersion among women

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Hyperthyroidism is associated with lengthening of ventricular repolarization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

High free thyroxine levels are associated with QTc prolongation in males

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

Cardiotoxicity of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371/JOURNAL.PONE.0030353

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3281826

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology

27 November 2018

1 reference

12 December 2020

Thyroid hormone and the cardiovascular system

1 reference

12 December 2020

Noninvasive evaluation of cardiac function in hypothyroidism. Response to gradual thyroxine replacement

1 reference

12 December 2020

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

1 reference

12 December 2020

Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0030353

Identifiers

DOI

0 references

0 references

0 references